Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1419&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1420&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1418&sort=title" }, "data": [ { "type": "Grant", "id": "9401", "attributes": { "award_id": "1R01DE031114-01", "title": "Validation of Smart Masks for Surveillance of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6680, "first_name": "Dena", "last_name": "Fischer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-12-21", "end_date": "2022-11-30", "award_amount": 348568, "principal_investigator": { "id": 6681, "first_name": "Jesse Vincent", "last_name": "Jokerst", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary. Vulnerable populations do not just need testing—they need surveillance. The ideal surveillance tool would operate in the background with minimal involvement of the population to be tested; it would be simple, affordable, reliable, and accurate. Unfortunately, no such surveillance system yet exists. Here, we propose a “smart mask” that changes colors when the wearer has been exposed to biomarkers (proteases) of COVID-19. These proteases are known to be in saliva, and the smart mask will concentrate the proteases from aerosolized saliva when the subject breathes and speaks through the smart mask. This is a simple yet novel approach to surveillance because most people are already wearing masks—especially in high- risk settings. Our first goal is to optimize the reagents that will monitor the proteases. We will customize the peptide sequences such that the reagents change color only when two key SARS proteases are present. After characterizing the colorimetric reagents, Aim 2 will integrate these reagents into an adhesive strip (i.e., a sticker) that can be affixed to any existing cloth or surgical mask. Aim 3 is validation with human subjects. First, we will use biobanked saliva samples that are confirmed to be either COVID-19-positive or COVID-19-negative. Next, we will evaluate how long people infected with SARS-CoV-2 must breathe through the smart mask before it changes colors. Finally, we will use the smart mask for surveillance of a population that is concurrently being tested regularly via PCR. We will calculate the sensitivity and specificity of the smart masks through comparison to PCR. We will measure true positives, true negatives, false positives, and false negatives and estimate needing 800 subjects, which is very feasible at our institution. Our team is well-suited to conduct this research because of Dr. Jokerst’s training colorimetric sensing; Drs. Penny, Knight, and Laurent have decades of human subjects research experience, and Dr. Tu offers biostatistical experience to confirm study design. This work could have a significant impact on the pandemic because our proposed design combines the simplicity of the home pregnancy test with the specificity of expensive viral-based assays. It is practical because it uses the masks that are already common in daily life and reports the presence of SARS viruses via a simple color change. While a vaccine will hopefully be deployed during the course of this work, the proteases evaluated here have been implicated in a variety of SARS viruses. Thus, this work will be useful should future pandemics emerge.", "keywords": [ "3-Dimensional", "Adhesives", "Biological Assay", "Biological Markers", "Biometry", "Bulla", "COVID-19", "COVID-19 diagnosis", "COVID-19 early detection", "COVID-19 surveillance", "COVID-19 susceptibility", "Caregivers", "Clinic", "Color", "Communities", "Complex", "Custom", "Data Coordinating Center", "Dialysis procedure", "Exposure to", "Future", "Goals", "Gold", "Health care facility", "Home", "Hospitals", "Human", "Human Resources", "Human Subject Research", "Individual", "Infrastructure", "Institution", "Laboratories", "Life", "Literature", "Masks", "Measures", "Methods", "Monitor", "N95 mask", "Outcome", "Papain", "Patient Care", "Patients", "Peptide Hydrolases", "Peptides", "Persons", "Population", "Predictive Value", "Pregnancy Tests", "Preparation", "Prisons", "RADx Radical", "Reagent", "Recombinants", "Reporter", "Reporting", "Research", "Research Design", "Respirators", "Risk", "SARS coronavirus", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 negative", "SARS-CoV-2 positive", "Saliva", "Sampling", "Sensitivity and Specificity", "Serology", "Severe Acute Respiratory Syndrome", "Skilled Nursing Facilities", "Specificity", "System", "Testing", "Time", "Training", "Vaccines", "Validation", "Viral", "Viral Load result", "Viral Physiology", "Virus", "Vulnerable Populations", "Work", "aerosolized", "base", "biobank", "coronavirus disease", "data sharing", "design", "detection limit", "experience", "high risk", "human subject", "infection risk", "innovation", "nanoGold", "novel strategies", "pandemic disease", "particle", "patient home care", "point of care", "protein aminoacid sequence", "saliva sample", "surgical mask", "test strip", "tool" ], "approved": true } }, { "type": "Grant", "id": "5054", "attributes": { "award_id": "4R01DE031114-02", "title": "Validation of Smart Masks for Surveillance of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 18078, "first_name": "Dena", "last_name": "Fischer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-12-21", "end_date": "2023-11-30", "award_amount": 432457, "principal_investigator": { "id": 18079, "first_name": "Jesse Vincent", "last_name": "Jokerst", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary. Vulnerable populations do not just need testing—they need surveillance. The ideal surveillance tool would operate in the background with minimal involvement of the population to be tested; it would be simple, affordable, reliable, and accurate. Unfortunately, no such surveillance system yet exists. Here, we propose a “smart mask” that changes colors when the wearer has been exposed to biomarkers (proteases) of COVID-19. These proteases are known to be in saliva, and the smart mask will concentrate the proteases from aerosolized saliva when the subject breathes and speaks through the smart mask. This is a simple yet novel approach to surveillance because most people are already wearing masks—especially in high- risk settings. Our first goal is to optimize the reagents that will monitor the proteases. We will customize the peptide sequences such that the reagents change color only when two key SARS proteases are present. After characterizing the colorimetric reagents, Aim 2 will integrate these reagents into an adhesive strip (i.e., a sticker) that can be affixed to any existing cloth or surgical mask. Aim 3 is validation with human subjects. First, we will use biobanked saliva samples that are confirmed to be either COVID-19-positive or COVID-19-negative. Next, we will evaluate how long people infected with SARS-CoV-2 must breathe through the smart mask before it changes colors. Finally, we will use the smart mask for surveillance of a population that is concurrently being tested regularly via PCR. We will calculate the sensitivity and specificity of the smart masks through comparison to PCR. We will measure true positives, true negatives, false positives, and false negatives and estimate needing 800 subjects, which is very feasible at our institution. Our team is well-suited to conduct this research because of Dr. Jokerst’s training colorimetric sensing; Drs. Penny, Knight, and Laurent have decades of human subjects research experience, and Dr. Tu offers biostatistical experience to confirm study design. This work could have a significant impact on the pandemic because our proposed design combines the simplicity of the home pregnancy test with the specificity of expensive viral-based assays. It is practical because it uses the masks that are already common in daily life and reports the presence of SARS viruses via a simple color change. While a vaccine will hopefully be deployed during the course of this work, the proteases evaluated here have been implicated in a variety of SARS viruses. Thus, this work will be useful should future pandemics emerge.", "keywords": [ "3-Dimensional", "Adhesives", "Biological Assay", "Biological Markers", "Biometry", "Bulla", "COVID-19", "COVID-19 diagnosis", "COVID-19 early detection", "COVID-19 surveillance", "COVID-19 susceptibility", "Caregivers", "Clinic", "Color", "Communities", "Complex", "Custom", "Data Coordinating Center", "Dialysis procedure", "Exposure to", "Future", "Goals", "Gold", "Health care facility", "Home", "Hospitals", "Human", "Human Resources", "Human Subject Research", "Individual", "Infrastructure", "Institution", "Laboratories", "Life", "Literature", "Masks", "Measures", "Methods", "Monitor", "N95 mask", "Outcome", "Papain", "Patient Care", "Patients", "Peptide Hydrolases", "Peptides", "Persons", "Population", "Predictive Value", "Pregnancy Tests", "Preparation", "Prisons", "RADx Radical", "Reagent", "Recombinants", "Reporter", "Reporting", "Research", "Research Design", "Respirators", "Risk", "SARS coronavirus", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 negative", "SARS-CoV-2 positive", "Saliva", "Sampling", "Sensitivity and Specificity", "Serology", "Severe Acute Respiratory Syndrome", "Skilled Nursing Facilities", "Specificity", "System", "Testing", "Time", "Training", "Vaccines", "Validation", "Viral", "Viral Load result", "Viral Physiology", "Virus", "Vulnerable Populations", "Work", "aerosolized", "base", "biobank", "coronavirus disease", "data sharing", "design", "detection limit", "experience", "high risk", "human subject", "infection risk", "innovation", "nanoGold", "novel strategies", "pandemic disease", "particle", "patient home care", "point of care", "protein aminoacid sequence", "saliva sample", "surgical mask", "test strip", "tool" ], "approved": true } }, { "type": "Grant", "id": "14941", "attributes": { "award_id": "5R01AG080635-02", "title": "Validation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse Populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 31608, "first_name": "MARYAM X", "last_name": "Ghaleh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-05-31", "award_amount": 2253049, "principal_investigator": { "id": 28013, "first_name": "Ali", "last_name": "Ezzati", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28014, "first_name": "Richard B.", "last_name": "LIPTON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28015, "first_name": "Laura A.", "last_name": "Rabin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "In-person administration is the current “gold-standard” for assessment of cognition and function in studies of Alzheimer’s disease and other dementia (ADRD). Remote neuropsychological assessment has been advocated to overcome various access barriers and decrease costs of neuropsychological services. Moreover, due to the pressing challenges and safety concerns imposed by the COVID-19 pandemic, there is an urgent need for robust methods for assessing and monitoring cognitive and functional status through remote assessments. The overall goal of the current project is to validate, refine, and calibrate the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for the assessment and monitoring of cognition and function in a diverse sample of initially dementia-free older adults. The toolbox will include measures from the Uniform Data Set, Neuropsychological Battery (UDSNB-3.0), complemented by frequently used tests in preclinical AD trials. In-person tests that pose challenges for remote administration will be replaced with tablet-based computerized tasks. We will recruit 600 dementia-free, racially/ethnically diverse (~ 1/3 non-Hispanic Black, 1/3 Hispanic, and 1/3 non- Hispanic White), community-residing participants aged ≥65 years. A randomized, counterbalanced design will be used to administer a comprehensive clinical and cognitive battery across both assessment modes (in-person vs. remote) separated by 2-6 weeks at baseline, with follow up visits at 18 and 36 months. Digital biomarkers (computerized tests and speech-based) and ADRD blood-based biomarkers will be collected. AIM 1: To evaluate the psychometric properties of remote cognitive tests and assess their validity against standard in-person tests. AIM 2: To evaluate comparability of longitudinal change in global cognition and within cognitive domains across modes of assessment (in-person vs remote) for the whole sample as well as subgroups defined by sex and race/ethnicity. AIM 3 (exploratory): To identify novel digital biomarkers that provide incremental validity for differentiating clinical and pathological disease stages, and for measuring and predicting cognitive and functional decline. Collectively, this study will validate remotely administered tests across different cognitive domains, provide evidence for cross-sectional and longitudinal validity, and provide normative data for remote tests in diverse populations. Our long-term goal is to develop an open-source, reliable and valid toolbox that would enable AD-researchers and clinicians to evaluate older adults from diverse backgrounds regardless of ability to attend in-person visits. 1", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12151", "attributes": { "award_id": "1R01AG080635-01A1", "title": "Validation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse Populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 10682, "first_name": "DALLAS", "last_name": "ANDERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-05-31", "award_amount": 2101898, "principal_investigator": { "id": 28013, "first_name": "Ali", "last_name": "Ezzati", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28014, "first_name": "Richard B.", "last_name": "LIPTON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28015, "first_name": "Laura A.", "last_name": "Rabin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "In-person administration is the current “gold-standard” for assessment of cognition and function in studies of Alzheimer’s disease and other dementia (ADRD). Remote neuropsychological assessment has been advocated to overcome various access barriers and decrease costs of neuropsychological services. Moreover, due to the pressing challenges and safety concerns imposed by the COVID-19 pandemic, there is an urgent need for robust methods for assessing and monitoring cognitive and functional status through remote assessments. The overall goal of the current project is to validate, refine, and calibrate the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for the assessment and monitoring of cognition and function in a diverse sample of initially dementia-free older adults. The toolbox will include measures from the Uniform Data Set, Neuropsychological Battery (UDSNB-3.0), complemented by frequently used tests in preclinical AD trials. In-person tests that pose challenges for remote administration will be replaced with tablet-based computerized tasks. We will recruit 600 dementia-free, racially/ethnically diverse (~ 1/3 non-Hispanic Black, 1/3 Hispanic, and 1/3 non- Hispanic White), community-residing participants aged ≥65 years. A randomized, counterbalanced design will be used to administer a comprehensive clinical and cognitive battery across both assessment modes (in-person vs. remote) separated by 2-6 weeks at baseline, with follow up visits at 18 and 36 months. Digital biomarkers (computerized tests and speech-based) and ADRD blood-based biomarkers will be collected. AIM 1: To evaluate the psychometric properties of remote cognitive tests and assess their validity against standard in-person tests. AIM 2: To evaluate comparability of longitudinal change in global cognition and within cognitive domains across modes of assessment (in-person vs remote) for the whole sample as well as subgroups defined by sex and race/ethnicity. AIM 3 (exploratory): To identify novel digital biomarkers that provide incremental validity for differentiating clinical and pathological disease stages, and for measuring and predicting cognitive and functional decline. Collectively, this study will validate remotely administered tests across different cognitive domains, provide evidence for cross-sectional and longitudinal validity, and provide normative data for remote tests in diverse populations. Our long-term goal is to develop an open-source, reliable and valid toolbox that would enable AD-researchers and clinicians to evaluate older adults from diverse backgrounds regardless of ability to attend in-person visits. 1", "keywords": [ "Acoustics", "Address", "Advocate", "Agreement", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease risk", "Amyloid beta-Protein", "Biological Markers", "Black race", "COVID-19 pandemic", "Calibration", "Caring", "Classification", "Clinical", "Clinical Trials", "Cognition", "Cognitive", "Cognitive aging", "Cohort Studies", "Communities", "Complement", "Data", "Data Collection", "Data Set", "Dementia", "Development", "Devices", "Digital biomarker", "Disease", "Disparity", "Elderly", "Electronic Health Record", "Ensure", "Ethnic Origin", "Ethnic Population", "Evaluation", "Frail Elderly", "Future", "Glial Fibrillary Acidic Protein", "Goals", "Grant", "Healthcare Systems", "Hispanic", "Impaired cognition", "Individual", "Intervention", "Measures", "Methods", "Modality", "Monitor", "Neuropsychological Tests", "Neuropsychology", "Not Hispanic or Latino", "Observational Study", "Participant", "Pathologic", "Pathology", "Patient Care", "Pattern", "Performance", "Persons", "Population Heterogeneity", "Property", "Psychometrics", "Race", "Randomized", "Research", "Research Personnel", "Risk", "Safety", "Sampling", "Semantics", "Services", "Speech", "Subgroup", "Tablets", "Telephone", "Testing", "Time", "Underserved Population", "Vaccination", "Validation", "Videoconferencing", "Visit", "blood-based biomarker", "clinical practice", "cognitive performance", "cognitive testing", "cohort", "computerized", "cost", "design", "digital", "ethnic diversity", "follow-up", "functional decline", "functional status", "human old age (65+)", "improved", "low socioeconomic status", "mild cognitive impairment", "neurofilament", "novel", "open source", "pandemic disease", "pre-clinical", "racial diversity", "racial population", "recruit", "remote administration", "remote assessment", "remote grading", "remote visit", "sex" ], "approved": true } }, { "type": "Grant", "id": "7887", "attributes": { "award_id": "1R01AG075959-01", "title": "Validation of Video Administration of a Modified UDSv3 Cognitive Battery", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 11650, "first_name": "Cerise", "last_name": "Elliott", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-01", "end_date": "2027-02-28", "award_amount": 1467486, "principal_investigator": { "id": 23734, "first_name": "STEPHEN R", "last_name": "RAPP", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1149, "ror": "", "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23735, "first_name": "Bonnie", "last_name": "Sachs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1149, "ror": "", "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This multi-site R01 aims to validate video-administered cognitive assessments for use by the Alzheimer’s Disease Research Centers (ADRCs) and other research programs whose activities have been interrupted by the COVID-19 pandemic, as well as for use in future initiatives when remote testing will enhance achievement of scientific goals. While face-to-face administration is the gold standard for cognitive assessments, conditions often arise that prevent participants from attending in-person visits. These barriers include transportation challenges, limited mobility, and financial hardship. There is also evidence that underserved populations, including rural populations and racial/ethnic minorities, are less likely to enroll in studies that require travel to an academic medical center for face-to-face testing. The proposed study will address these challenges by utilizing a video-adapted battery incorporating the Uniform Data Set version 3 (UDSv3) measures with additional measures that may serve as alternatives for UDSv3 measures not adaptable to video administration. We propose to fully validate these assessment tools for remote administration in partnership with the NIA and the National Alzheimer’s Coordinating Center (NACC), and carried out by a consortium of 12 ADRCs. Pilot data was gathered from 88 Wake Forest ADRC participants, deemed by in-person testing and adjudication to have normal cognition, MCI, or dementia, who were tested either by phone or video. Data show high participant ratings of tolerability, feasibility, and preference for video versus telephone assessment. There is also high concordance between video-administered and in- person test scores. Based on this collective data, we plan to fully validate a video-version of the UDSv3 battery in a range of cognitively, ethnically, and geographically diverse participants. We propose to administer remote video cognitive assessments, paired alongside annual in-person cognitive assessments, in counterbalanced order, to 500 existing participants from 12 ADRCs utilizing a computer tablet device, including those previously adjudicated as having normal cognition, MCI and dementia. Participants’ ratings of satisfaction with test condition and preference of test modality will be obtained, in addition to the psychometric characteristics of the video battery relative to face-to-face administration, including concurrent validity, and estimates of relative bias overall and across important subgroups (age, ethnicity, cognitive status) and mode of administration of individual tests. Concordance between adjudication outcomes will also be examined to assess the ability of the battery to distinguish normal cognition, MCI and dementia. We will assess the sensitivity of the video battery to detect longitudinal change in cognition in ADRC participants by repeating counterbalanced, in-person and remote assessments 2 years following initial evaluation. Completion of this project is critical to the ongoing success of cognitive assessment in the ADRC network.", "keywords": [ "Academic Medical Centers", "Achievement", "Acute Respiratory Distress Syndrome", "Address", "Advisory Committees", "Affect", "Age", "Agreement", "Alzheimer&apos", "s Disease", "Amyotrophic Lateral Sclerosis", "Assessment tool", "Attention", "COVID-19 pandemic", "Characteristics", "Classification", "Clinical", "Cognition", "Cognitive", "Data", "Data Collection", "Data Set", "Dementia", "Education", "Elderly", "Enrollment", "Episodic memory", "Ethnic Origin", "Evaluation", "Failure", "Financial Hardship", "Frail Elderly", "Future", "Geographic Locations", "Geography", "Goals", "Gold", "Individual", "Interruption", "Language", "Measures", "Medical center", "Minority", "Modality", "Neuropsychology", "Outcome", "Participant", "Persons", "Population", "Protocols documentation", "Psychometrics", "Race", "Research", "Rural Population", "Short-Term Memory", "Site", "Standardization", "Subgroup", "Tablet Computer", "Telephone", "Testing", "Time", "Transportation", "Traumatic Brain Injury", "Travel", "Underserved Population", "United States National Institutes of Health", "Update", "Validation", "Visit", "adjudicate", "adjudication", "base", "clinical care", "cognitive testing", "ethnic minority population", "executive function", "forest", "meetings", "metropolitan", "mild cognitive impairment", "preference", "prevent", "programs", "racial and ethnic", "recruit", "response", "satisfaction", "success", "tool", "virtual", "working group" ], "approved": true } }, { "type": "Grant", "id": "9072", "attributes": { "award_id": "3UM1AI069439-15S1", "title": "Vanderbilt CTU SARS-CoV-2 Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24859, "first_name": "Donna E.", "last_name": "Germuga", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-02", "end_date": "2020-11-30", "award_amount": 558406, "principal_investigator": { "id": 24871, "first_name": "David W", "last_name": "Haas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24872, "first_name": "Spyros A", "last_name": "Kalams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24873, "first_name": "Rachel Margaret", "last_name": "Presti", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) required a rapid, coordinated response. The pandemic has interfered with many other important endeavors, including NIH-sponsored non-COVID HIV clinical trials. We need robust plans to implement measures to expand SARS-CoV-2, allowing research units to resume studies being conducted on HIV, while maintaining the safety and well-being of participants and staff. To this end, we have developed strategies relying on a combination of testing for active disease, evaluating seroprevalence, and conducting operations in ways that enforce social distancing and utilization of personal protective equipment (PPE). This project is being implemented at the Vanderbilt Therapeutics Clinical Research Site (VT-CRS), and the Washington University Prevention & Therapeutics (WPT) CRS. This strategy will comprise two aims that involve research participants, their household contacts, and staff: Aim 1) To utilize resources obtained through this administrative supplement to expand SARS-CoV-2 testing within the regions of our Clinical Research Sites; and Aim 2) To utilize resources obtained through this administrative supplement to more quickly and fully resume on-site research activities at our Clinical Research Sites. Among the activities to be implemented are universal testing of study participants for infection by SARS-CoV-2 PCR prior to study visits, either by staff during parking lot drive-through visits or self- collected remotely by study participants. At one CRS, testing will also be offered to adult household contacts of study participants. There will be active screening for symptoms of COVID-19. There will be SARS-CoV-2 antibody testing at the beginning and end of the project period, of staff and/or study participants. This project will substantially expanding SARS-CoV-2 testing, and expedite the opening of our NIAID-funded CRSs. In addition, the experience and information gained during this project will inform future strategies to further expand testing and facilitate clinical trials operations.", "keywords": [ "2019-nCoV", "Academic Medical Centers", "Administrative Supplement", "Adult", "Antibodies", "Antigens", "Area", "Businesses", "COVID-19", "COVID-19 pandemic", "Caring", "Clinical Research", "Clinical Trials", "Collection", "Communicable Diseases", "Contact Tracing", "Coughing", "Coupled", "Data", "Diagnostic tests", "Disease", "Disease Outbreaks", "Ensure", "Environment", "Epidemic", "Epidemiology", "Equipment", "Evaluation", "Fever", "Funding", "Funding Opportunities", "Future", "Grant", "HIV", "Health Personnel", "Healthcare", "Healthcare Systems", "Hour", "Household", "Individual", "Infection", "Infection Control", "Location", "Malaise", "Masks", "Measures", "Medical Records", "Morbidity - disease rate", "Nasal turbinate bone structure", "National Institute of Allergy and Infectious Disease", "Nose", "Occupational Health", "Participant", "Patients", "Personal Satisfaction", "Play", "Population", "Prevention", "Recommendation", "Research", "Research Activity", "Resistance", "Resources", "Respiratory Tract Infections", "Role", "Safety", "Schedule", "Serologic tests", "Seroprevalences", "Sexually Transmitted Diseases", "Shortness of Breath", "Site", "Social Distance", "Specimen", "Sputum", "Swab", "Symptoms", "Syndrome", "Tennessee", "Testing", "Therapeutic", "Treatment Efficacy", "Tuberculosis", "U-Series Cooperative Agreements", "United States", "United States National Institutes of Health", "Universities", "Vaccines", "Visit", "Washington", "base", "clinical research site", "common symptom", "experience", "follow-up", "health care service utilization", "mortality", "operation", "pandemic disease", "respiratory", "response", "sample collection", "scale up", "screening", "success" ], "approved": true } }, { "type": "Grant", "id": "7705", "attributes": { "award_id": "3UL1TR002243-04S4", "title": "Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21334, "first_name": "Rashmi", "last_name": "Gopal-Srivastava", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-18", "end_date": "2022-02-28", "award_amount": 562991, "principal_investigator": { "id": 23495, "first_name": "Gordon R", "last_name": "Bernard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23394, "first_name": "CONSUELO HOPKINS", "last_name": "WILKINS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub with these aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies that propel transdisciplinary research approaches, and integrate proven community engagement principles to stakeholders for all stages of research; 2) Develop, implement and disseminate informatics and data organization methods to promulgate research efficiency, quality, and preparedness and integrate data collection in the conduct of pragmatic trials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries; 4) Measurably improve the efficiency, quality, and representativeness of C&T studies by enhancing and systematically integrating services and programs that support highest quality research initiation and conduct; 5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration with the TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapid feasibility and recruitment methods and practices, and creating and disseminating novel clinical trial designs and methodologies; and 6) Utilize unique strengths leveraging novel resources BioVU and PheWAS to guide drug development and repurposing.", "keywords": [ "2019-nCoV", "Agreement", "Antibodies", "Binding", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Clinical Research", "Clinical Trials Design", "Collaborations", "Communities", "Country", "Data", "Data Collection", "Ensure", "Health Sciences", "Immunity", "Individual", "Infection", "Informatics", "Institutes", "Institution", "Knowledge", "Legal", "Measurable", "Measures", "Medical", "Methodology", "Methods", "Mission", "Multi-Institutional Clinical Trial", "Outcome", "Participant", "Plasma", "Randomized Clinical Trials", "Readiness", "Research", "Research Infrastructure", "Resources", "Safety", "Science", "Transfusion", "Translational Research", "Translations", "United States", "Viral", "Virus", "clinical efficacy", "drug development", "improved", "novel", "patient subsets", "pragmatic trial", "programs", "recruit", "service programs", "skills", "translational study" ], "approved": true } }, { "type": "Grant", "id": "8150", "attributes": { "award_id": "3UM1AI148452-02S3", "title": "Vanderbilt Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 9257, "first_name": "Gail H.", "last_name": "Tauscher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-04-23", "end_date": "2021-11-30", "award_amount": 614901, "principal_investigator": { "id": 9258, "first_name": "Clarence Buddy", "last_name": "Creech", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Director/Principal Investigator (Last, First, Middle): Creech, Clarence B Supplement Abstract Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults This project supports specific aims 2, 3, and 4 from the Vanderbilt UM1 application and is consistent with the terms of award. More specifically, the purpose of this activity is to evaluate a variant SARS-CoV-2 vaccine (mRNA-1273.351) in vaccine-naïve individuals. COVID-19 has led to widespread morbidity and mortality and though currently authorized vaccines are highly efficacious, the emergence of variant viruses that may escape disease- and vaccine-induced immunity requires additional vaccines to be evaluated. Specific Aim 2: Conduct multi-site and single site research evaluating the safety, efficacy, and immunogenicity of novel interventions. We propose a single site at VUMC that will enroll approximately 30 healthy adults into a study of mRNA-1273.351. Specific Aim 3: Evaluate immune responses resulting from natural infection or vaccine administration. Central to this work will be the evaluation of immune responses to a novel vaccine candidate. Specific Aim 4: Train future leaders in vaccinology and clinical trials. Similar to other studies conducted for COVID thus far, junior faculty and fellows will be trained in vaccine clinical trials and pandemic responsiveness. This request is to support COVID-19 clinical research, including CoVPN site preparation, trial implementation, and enrollment of participants in the above COVID-19 clinical research study. Work will include, but is not limited to: site preparation activities; protocol development/revision; clinical trial activities; pharmacy support; laboratory processing and storage of samples; laboratory assays; quality oversight; and manuscript development, as appropriate. PHS 398/2590 (Rev. 06/09) Page Continuation Format Page", "keywords": [ "2019-nCoV", "Adult", "Award", "Biological Assay", "COVID-19", "COVID-19 Prevention Network", "COVID-19 vaccine", "Clinical Research", "Clinical Trials", "Coronavirus", "Development", "Disease", "Enrollment", "Evaluation", "Faculty", "Future", "Immune response", "Individual", "Infection", "Intervention", "Laboratories", "Manuscripts", "Measures", "Moderna COVID-19 vaccine", "Morbidity - disease rate", "Pharmacy facility", "Phase", "Preparation", "Principal Investigator", "Randomized", "Research", "SARS-CoV-2 variant", "Safety", "Sampling", "Site", "Training", "Vaccinated", "Vaccine Clinical Trial", "Vaccines", "Variant", "Virus", "Work", "coronavirus disease", "immunogenicity", "mortality", "novel", "novel vaccines", "open label", "pandemic disease", "participant enrollment", "programs", "protocol development", "research study", "safety study", "vaccine candidate", "vaccine evaluation", "vaccine-induced immunity", "vaccinology" ], "approved": true } }, { "type": "Grant", "id": "5608", "attributes": { "award_id": "3UM1AI148452-02S1", "title": "Vanderbilt Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19420, "first_name": "Gail H.", "last_name": "Tauscher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-25", "end_date": "2021-11-30", "award_amount": 192338, "principal_investigator": { "id": 19421, "first_name": "Clarence Buddy", "last_name": "Creech", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research studies across a wide variety of pathogens, infectious diseases, and populations as a Vaccine and Treatment Evaluation Unit (VTEU). Vanderbilt University Medical Center was among the first VTEUs funded and has led pivotal studies of influenza, pertussis, pneumococcus, smallpox, and malaria vaccines. The Vanderbilt VTEU has a proven capacity to enroll healthy populations rapidly, including participating in two NIH- directed influenza pandemic responses since 2009, as well as expertise enrolling special populations such as pregnant women, infants and children, adults with underlying medical comorbidities, and the elderly. In the current application, we have expanded our ability to recruit across the lifespan and across multiple pathogens, including increased expertise in sexually transmitted infections, malaria, and novel approaches to conducting clinical trial visits in the home setting. The Vanderbilt VTEU has also led efforts to train the next generation of vaccinologists and clinical trial experts in infectious diseases, including the development of a vaccinology fellowship, participation of fellows and junior faculty in protocol teams and data safety committees, and encouraging concept development by junior faculty. The Vanderbilt VTEU is also committed to working collaboratively with the newly formed Infectious Diseases Leadership Group to articulate priorities for ID research.", "keywords": [ "Academic Medical Centers", "Adult", "Age", "Area", "Award", "Bacterial Infections", "Biological", "Biological Assay", "Child", "Childhood", "Clinical", "Clinical Investigator", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Conduct Clinical Trials", "Data", "Development", "Disease", "Education", "Elderly", "Emerging Communicable Diseases", "Enrollment", "Environment", "Evaluation", "Faculty", "Feasibility Studies", "Fellowship", "Fostering", "Funding", "Geography", "Goals", "Home", "Human", "Immune response", "Immunity", "Immunization", "Immunologist", "Individual", "Infant", "Infection", "Influenza", "Institution", "International", "Intervention", "Laboratories", "Laboratory Scientists", "Lead", "Leadership", "Licensure", "Longevity", "Malaria", "Malaria Vaccines", "Medical", "Medical center", "Mentors", "Mentorship", "Methods", "Modeling", "Mycoses", "Nurses", "Parasitic infection", "Pathogenesis", "Pennsylvania", "Pertussis Vaccine", "Peru", "Pharmaceutical Preparations", "Phase", "Physicians", "Pneumococcal vaccine", "Population", "Population Heterogeneity", "Positioning Attribute", "Pregnant Women", "Prevention", "Principal Investigator", "Procedures", "Process", "Protocols documentation", "Research", "Research Infrastructure", "Research Personnel", "Safety", "Scientist", "Sexually Transmitted Diseases", "Site", "Smallpox Vaccine", "Special Population", "Standardization", "Systems Biology", "Tissues", "Training", "United States National Institutes of Health", "Universities", "Vaccination", "Vaccine Research", "Vaccines", "Viral", "Virus Diseases", "Visit", "Washington", "Work", "antibiotic resistant infections", "base", "career", "career development", "clinical research site", "comorbidity", "design", "early phase clinical trial", "emerging pathogen", "ethnic diversity", "experience", "immunogenicity", "influenza virus vaccine", "innovation", "next generation", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic influenza", "pathogen", "recruit", "research study", "respiratory", "response", "tool", "vaccine trial", "vaccinology", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "6411", "attributes": { "award_id": "3UM1AI148452-01S1", "title": "Vanderbilt Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21559, "first_name": "Gail H.", "last_name": "Tauscher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-25", "end_date": "2022-11-30", "award_amount": 842642, "principal_investigator": { "id": 21560, "first_name": "Clarence Buddy", "last_name": "Creech", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research studies across a wide variety of pathogens, infectious diseases, and populations as a Vaccine and Treatment Evaluation Unit (VTEU). Vanderbilt University Medical Center was among the first VTEUs funded and has led pivotal studies of influenza, pertussis, pneumococcus, smallpox, and malaria vaccines. The Vanderbilt VTEU has a proven capacity to enroll healthy populations rapidly, including participating in two NIH- directed influenza pandemic responses since 2009, as well as expertise enrolling special populations such as pregnant women, infants and children, adults with underlying medical comorbidities, and the elderly. In the current application, we have expanded our ability to recruit across the lifespan and across multiple pathogens, including increased expertise in sexually transmitted infections, malaria, and novel approaches to conducting clinical trial visits in the home setting. The Vanderbilt VTEU has also led efforts to train the next generation of vaccinologists and clinical trial experts in infectious diseases, including the development of a vaccinology fellowship, participation of fellows and junior faculty in protocol teams and data safety committees, and encouraging concept development by junior faculty. The Vanderbilt VTEU is also committed to working collaboratively with the newly formed Infectious Diseases Leadership Group to articulate priorities for ID research.", "keywords": [ "Academic Medical Centers", "Adult", "Age", "Area", "Award", "Bacterial Infections", "Biological", "Biological Assay", "Child", "Childhood", "Clinical", "Clinical Investigator", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Conduct Clinical Trials", "Data", "Development", "Disease", "Education", "Elderly", "Emerging Communicable Diseases", "Enrollment", "Environment", "Evaluation", "Faculty", "Feasibility Studies", "Fellowship", "Fostering", "Funding", "Geography", "Goals", "Home environment", "Human", "Immune response", "Immunity", "Immunization", "Immunologist", "Individual", "Infant", "Infection", "Influenza", "Institution", "International", "Intervention", "Laboratories", "Laboratory Scientists", "Lead", "Leadership", "Licensure", "Longevity", "Malaria", "Malaria Vaccines", "Medical", "Medical center", "Mentors", "Mentorship", "Methods", "Modeling", "Mycoses", "Nurses", "Parasitic infection", "Pathogenesis", "Pennsylvania", "Pertussis Vaccine", "Peru", "Pharmaceutical Preparations", "Phase", "Physicians", "Pneumococcal vaccine", "Population", "Population Heterogeneity", "Positioning Attribute", "Pregnant Women", "Prevention", "Principal Investigator", "Procedures", "Process", "Protocols documentation", "Research", "Research Infrastructure", "Research Personnel", "Safety", "Scientist", "Sexually Transmitted Diseases", "Site", "Smallpox Vaccine", "Standardization", "Systems Biology", "Tissues", "Training", "United States National Institutes of Health", "Universities", "Vaccination", "Vaccine Research", "Vaccines", "Viral", "Virus Diseases", "Visit", "Washington", "Work", "antibiotic resistant infections", "base", "career", "career development", "clinical research site", "comorbidity", "design", "early phase clinical trial", "ethnic diversity", "experience", "immunogenicity", "influenza virus vaccine", "innovation", "named group", "next generation", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic influenza", "pathogen", "recruit", "research study", "respiratory", "response", "tool", "vaccine trial", "vaccinology", "volunteer" ], "approved": true } } ], "meta": { "pagination": { "page": 1419, "pages": 1442, "count": 14420 } } }